Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Malignant Melanoma

Free Subscription Articles published in Anticancer Res Retrieve available abstracts of 53 articles: HTML format

Single Articles

September 2026
1. MARCHESE PV, Zannini I, DE Biase D, Corti B, et al
   Exploring the Role of TERT Promoter Mutations in Advanced Melanoma Treated With BRAF/MEK Inhibitors or Immune Checkpoint Inhibitors.
   Anticancer Res. 2026;46:5013-5029.
   PubMed     Abstract available
   
   
   
2. BROCK LF, Demirors B, Godbole N, Bowers JC, et al
   Regional Disparities in Socioeconomic Factors and Advanced-stage Presentation in Melanoma: A National Cancer Database Analysis (2004-2020).
   Anticancer Res. 2026;46:4985-4991.
   PubMed     Abstract available
   
   
   
3. POPP R, Elston D
   Circadian Rhythm Disruption and Cutaneous Carcinogenesis.
   Anticancer Res. 2026;46:4791-4796.
   PubMed     Abstract available
   
   
   
4. CHO H, Zheng Z, Zhang M, Seo J, et al
   Mechanical Stress as a Pathomechanism of Plantar Acral Melanoma.
   Anticancer Res. 2026;46:4813-4826.
   PubMed     Abstract available
   
   
   August 2026
5. PARK NY, Park HS, Kim C, Kim SG, et al
   Tumor-secreted Autocrine Motility Factor: Pro-melanogenic Activity at Low Doses and Reversal Effect at Higher Doses Combined With Glycyrrhetinic Acid.
   Anticancer Res. 2026;46:4323-4329.
   PubMed     Abstract available
   
   
   
6. ANWAR M, Melendez-Torres GJ, Frazer RD
   A Single Center Real-world Observational Study of Response to Dacarbazine or Dacarbazine Combinations in Metastatic Melanoma Refractory to Immunotherapy.
   Anticancer Res. 2026;46:4471-4477.
   PubMed     Abstract available
   
   
   July 2026
7. MAJEWSKA O, Kulig P, Markiewicz D, Brzewski P, et al
   Clinical Features of Malignant Melanoma of the Skin Versus Suspicious Benign Skin Lesions.
   Anticancer Res. 2026;46:4087-4098.
   PubMed     Abstract available
   
   
   
8. IKUSHIMA C, Nakamura K, Furuta K, Iwata E, et al
   Dacarbazine Resistance in Melanoma Is Driven by Cell Cycle Dysregulation Stemming from Altered Cyclin D1, GSK-3beta, and p21 Expression.
   Anticancer Res. 2026;46:3797-3804.
   PubMed     Abstract available
   
   
   March 2026
9. MAIMON O, Nisman B, Ben-David I, Kuznetz A, et al
   Autologous Tumor Vaccination in Melanoma and Colon Cancer Patients With Recurrent Liver Metastases: A Case Series.
   Anticancer Res. 2026;46:1569-1575.
   PubMed     Abstract available
   
   
   December 2025
10. CHANDRASEKARAN R, Lu ML, Dwivedi C, Bommareddy A, et al
    Growth Suppression and Selective Disruption of F-Actin by alpha-Santalol in Human Melanoma Cells.
    Anticancer Res. 2025;45:5399-5407.
    PubMed     Abstract available
    
    
    November 2025
11. CHADWICK WF, Ganesh S, Dadzie AK, Ebrahimi B, et al
    Clinical Applications of Artificial Intelligence in Uveal Melanoma.
    Anticancer Res. 2025;45:4669-4681.
    PubMed     Abstract available
    
    
    October 2025
12. ANESTOPOULOS I, Paraskevaidis I, Kyriakou S, Trafalis DT, et al
    Isothiocyanates Enhance the Anti-melanoma Effect of Entinostat Through Modulation of Apoptosis and HDACs' Expression Patterns in an In Vitro Model of Human Malignant Melanoma.
    Anticancer Res. 2025;45:4151-4167.
    PubMed     Abstract available
    
    
    September 2025
13. BRUNNER AS, Haddad S, Weise JJ, Wagenpfeil S, et al
    Malignant Melanoma: The Relationship Between Sunscreen Use and Cancer Risk - A Systematic Review and Meta-analysis.
    Anticancer Res. 2025;45:3595-3603.
    PubMed     Abstract available
    
    
    August 2025
14. AZUMI J, Takeda T, Shimada Y, Aso H, et al
    Combination of 3-(Trihydroxygermyl)propanoic Acid (THGP) and Lipopolysaccharide Promotes Macrophage Differentiation to M1, and Antitumor Activity.
    Anticancer Res. 2025;45:3425-3440.
    PubMed     Abstract available
    
    
    
15. YAMADA T, Iwasawa T, Shimizu Y, Kato K, et al
    Resveratrol Enhances Sulfasalazine-induced Ferroptosis by Promoting Iron Ion Accumulation and Lipid Peroxidation in Cancer Cells.
    Anticancer Res. 2025;45:3231-3244.
    PubMed     Abstract available
    
    
    June 2025
16. SUZUKI Y, Usuki S, Nishizawa M, Tanaka N, et al
    Acyclic Retinoid Overcomes Vemurafenib Resistance in Melanoma Cells via Dual Inhibition of MAPK and PI3K/AKT/mTOR Pathways.
    Anticancer Res. 2025;45:2265-2278.
    PubMed     Abstract available
    
    
    
17. YOON HS, Park YG, Cho DY, Kim JS, et al
    Antitumor Activity of Ex Vivo Expanded Tumor Antigen Priming Cytotoxic T Cells Against Malignant Melanoma.
    Anticancer Res. 2025;45:2339-2350.
    PubMed     Abstract available
    
    
    May 2025
18. YOSHIKAWA N, Ikushima C, Tanaka N, Iwata E, et al
    Role of Platelet Interactions in Promoting Melanoma Malignancy With Insights into Proliferation, Cyclin D1 Expression, and Migration.
    Anticancer Res. 2025;45:1927-1934.
    PubMed     Abstract available
    
    
    
19. DICKE J, Hero L, Kuhl S, Goldbrunner R, et al
    Expression of YAP1 and TAZ in Melanoma-, Bronchial- and Breast Carcinoma Brain Metastasis: Primary vs. Relapsed Tumors.
    Anticancer Res. 2025;45:1807-1812.
    PubMed     Abstract available
    
    
    April 2025
20. YAMASHITA SN, Tanaka Y, Islam S, Kitagawa T, et al
    Increased Expression of DDX39 in Uveal Melanoma Is Associated With Patient Prognosis.
    Anticancer Res. 2025;45:1661-1666.
    PubMed     Abstract available
    
    
    March 2025
21. ZUPA A, Vita G, Omer LC, Calice G, et al
    NRAS(Q61K/R/L) Mutant Allele Frequency in Melanoma and its Correlation With Clinicopathological Characteristics.
    Anticancer Res. 2025;45:1015-1024.
    PubMed     Abstract available
    
    
    
22. POPP R, Savaliya BP, Raikot SR, Ahmed SH, et al
    Impact of Surgical Refusal on Overall Survival in Patients With Melanoma: A Comprehensive Analysis.
    Anticancer Res. 2025;45:1063-1070.
    PubMed     Abstract available
    
    
    February 2025
23. GKIONIS IG, Tzardi M, Alegakis A, Datseri G, et al
    Cyclin E Expression and p16 Loss Are Strong Prognostic Biomarkers in Primary Invasive Cutaneous Melanoma.
    Anticancer Res. 2025;45:625-637.
    PubMed     Abstract available
    
    
    January 2025
24. HASHIGUCHI S, Tanaka T, Mano R, Kondo S, et al
    SLC7A11/xCT-mediated Cystine Uptake Regulates Intracellular Glutathione and Promotes Antioxidant Defense in Lymphatic Endothelial Cells.
    Anticancer Res. 2025;45:65-71.
    PubMed     Abstract available
    
    
    
25. HADDAD S, Weise JJ, Wagenpfeil S, Vogt T, et al
    Malignant Melanoma: Vitamin D Status as a Risk and Prognostic Factor - Meta-analyses and Systematic Review.
    Anticancer Res. 2025;45:27-37.
    PubMed     Abstract available
    
    
    December 2024
26. BASU D
    Therapeutic Strategies in Neurocutaneous Melanocytosis.
    Anticancer Res. 2024;44:5157-5167.
    PubMed     Abstract available
    
    
    
27. SIN J, Kiosea M, Kiosea N, Mahdavi K, et al
    Investigation of Effectiveness of Nowarta110 Against Murine Malignant Melanoma in an Implanted Animal Model.
    Anticancer Res. 2024;44:5219-5224.
    PubMed     Abstract available
    
    
    
28. KANAI M, Shinagawa A, Ota M, Virgona N, et al
    Resveratrol Can Differentiate Human Melanoma Stem-like Cells from Spheroids Treated With All-trans Retinoic Acid.
    Anticancer Res. 2024;44:5283-5292.
    PubMed     Abstract available
    
    
    
29. CHO Y, Kim HS
    Immunohistochemical Expression and Significance of Preferentially Expressed Antigen in Melanoma (PRAME) in Gynecological Tumors: A Single-institution Retrospective Analysis.
    Anticancer Res. 2024;44:5515-5524.
    PubMed     Abstract available
    
    
    September 2024
30. FRACCAROLI A, Barnikel M, Scheubeck G, Buchstab O, et al
    Stealthy Invader: Clinically Inapparent But Rapidly Progressive Multifocal Metastatic Melanoma Unveiled as Root Cause of Liver Failure.
    Anticancer Res. 2024;44:4127-4132.
    PubMed     Abstract available
    
    
    
31. GAO YU, Wendt S, Krohn S, Alammar M, et al
    Evaluation of Pan-RAF Inhibitor LY3009120 on Human Uveal Melanoma Cell Line 92-1.
    Anticancer Res. 2024;44:3843-3848.
    PubMed     Abstract available
    
    
    
32. MA W, Li Z, Wen J, Yan S, et al
    The Expression and Prognostic Value of Multiple Glucose Transporters in Cutaneous Melanoma.
    Anticancer Res. 2024;44:3747-3756.
    PubMed     Abstract available
    
    
    August 2024
33. JU M, Minami K, Katsuki S, Takenaka W, et al
    Synergistic Effects of Melatonin on Radiosensitization in Carbon-ion Radiotherapy.
    Anticancer Res. 2024;44:3295-3306.
    PubMed     Abstract available
    
    
    
34. SURESHKUMAR H, Eathara A, Datta A, Alahmadi R, et al
    Association Between Uveal Melanoma and Allostatic Load.
    Anticancer Res. 2024;44:3375-3380.
    PubMed     Abstract available
    
    
    June 2024
35. WEN X, Han M, Hosoya M, Toshima R, et al
    Identification of BRAF Inhibitor Resistance-associated lncRNAs Using Genome-scale CRISPR-Cas9 Transcriptional Activation Screening.
    Anticancer Res. 2024;44:2349-2358.
    PubMed     Abstract available
    
    
    March 2024
36. FERNANDO PDSM, Zhen AX, Piao MJ, Herath HMUL, et al
    Naringenin Induces Cellular Apoptosis in Melanoma Cells via Intracellular ROS Generation.
    Anticancer Res. 2024;44:1079-1086.
    PubMed     Abstract available
    
    
    February 2024
37. POPP K, Popp R, Bansal S, Sharan S, et al
    Disparities in Time-to-treatment for Patients With Melanoma.
    Anticancer Res. 2024;44:631-637.
    PubMed     Abstract available
    
    
    
38. SCALIA G, Silven MP, Costanzo R, Porzio M, et al
    Intraventricular Cerebral Metastases: A Comprehensive Systematic Review.
    Anticancer Res. 2024;44:453-462.
    PubMed     Abstract available
    
    
    January 2024
39. CESAR MCM, Mortara RA, Souza VS, Alves VRG, et al
    Peptide L13S Derived from the BRN2 POU Domain Reduces Metastasis In Vivo and Inhibits Cell Migration and Invasion In Vitro.
    Anticancer Res. 2024;44:71-84.
    PubMed     Abstract available
    
    
    
40. WALZ SN, Martineau J, Scampa M, Madduri S, et al
    Incidence Trends of Melanoma of the Lower Limbs and Hips in the United States: A Surveillance, Epidemiology, and End Results Analysis 2000-2019.
    Anticancer Res. 2024;44:239-247.
    PubMed     Abstract available
    
    
    
41. KELEMEN G, Egyud Z, Dobi A, Varga L, et al
    Survival Benefit of Stereotactic Radiotherapy in the Complex Management of Metastatic Melanoma.
    Anticancer Res. 2024;44:205-212.
    PubMed     Abstract available
    
    
    October 2023
42. GLASER N, Petzold A, Wessely A, Kaufmann MD, et al
    Threshold Optimization for Tumor Markers S100b and MIA in Uveal Melanoma - A Single Center Analysis.
    Anticancer Res. 2023;43:4525-4532.
    PubMed     Abstract available
    
    
    
43. TASSAVOR M, Martin BJ, Glazer AM
    The Integrated i31-GEP Test Outperforms the MSKCC Nomogram at Predicting SLN Status in Melanoma Patients.
    Anticancer Res. 2023;43:4511-4516.
    PubMed     Abstract available
    
    
    
44. DURZYNSKA M, Dos Santos FLC, Matuszczyk A, Derezinska-Wolek E, et al
    Prognostic Implications of PRAME Expression and Clinicopathological Factors in Sinonasal Mucosal Melanoma: A Single-center Cohort Study of 30 Cases.
    Anticancer Res. 2023;43:4551-4557.
    PubMed     Abstract available
    
    
    September 2023
45. WALZ SN, Martineau J, Scampa M, Madduri S, et al
    Melanoma of the Lower Limbs and Hips: A Surveillance, Epidemiology, and End Results Analysis of Epidemiology and Survival 2000-2019.
    Anticancer Res. 2023;43:4105-4113.
    PubMed     Abstract available
    
    
    August 2023
46. KIM Y, Kim JE, Lee DY, Choi JU, et al
    T Cells Expressing CAR Equipped With Extracellular Domain of BTLA Are Effective Against HVEM-over-expressing Melanoma Cell Lines.
    Anticancer Res. 2023;43:3419-3427.
    PubMed     Abstract available
    
    
    June 2023
47. WANG CH, Wang LK, Wu CC, Chen ML, et al
    TIG1 Inhibits the mTOR Signaling Pathway in Malignant Melanoma Through the VAC14 Protein.
    Anticancer Res. 2023;43:2635-2643.
    PubMed     Abstract available
    
    
    
48. HIPPNER-KUNICKA M, Laszkiewicz A, Skrzymowska J, Biecek P, et al
    Overexpression of c-MYC Promoter Binding Protein-1 Enhances Proliferation and Glucose Metabolism of Melanoma Cells Lines.
    Anticancer Res. 2023;43:2527-2538.
    PubMed     Abstract available
    
    
    April 2023
49. FRIEDLANDER P, Morgan LR, Benes EN, Rodgers AH, et al
    Preclinical Activity of 4-Demethyl-4-cholesteryloxycarbonylpenclomedine in Melanoma.
    Anticancer Res. 2023;43:1407-1413.
    PubMed     Abstract available
    
    
    
50. GRUJIC M, Nguyen T, Hechard T, Wang H, et al
    Phenotypic Switch and Growth of Melanoma Spheroids in the Presence of Mast Cells: Potential Impact of Nutrient-starvation Effects.
    Anticancer Res. 2023;43:1415-1426.
    PubMed     Abstract available
    
    
    
51. JARELL A, Fernandes N
    Letter to the Editor: RE: de Gruijl and Armstrong: Cutaneous Melanoma: Sheep in Wolves Clothing? Anticancer Res 42(10): 5021-5025, 2022.
    Anticancer Res. 2023;43:1873-1874.
    PubMed    
    
    
    
52. SASAKI K, Hirohashi Y, Murata K, Minowa T, et al
    SOX10 Inhibits T Cell Recognition by Inducing Expression of the Immune Checkpoint Molecule PD-L1 in A375 Melanoma Cells.
    Anticancer Res. 2023;43:1477-1484.
    PubMed     Abstract available
    
    
    March 2023
53. POOMMARAPAN K, Rummaneethorn P, Srisubat A, Suwanpidokkul N, et al
    Gene Profiling of Cannabis-sativa-mediated Apoptosis in Human Melanoma Cells.
    Anticancer Res. 2023;43:1221-1237.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum